Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)

被引:58
作者
Curigliano, Giuseppe [1 ,2 ]
Hu, Xichun [3 ]
Dent, Rebecca Alexandra [4 ]
Yonemori, Kan [5 ]
Barrios Sr, Carlos H. [6 ]
O'Shaughnessy, Joyce [7 ]
Wildiers, Hans [8 ]
Zhang, Qingyuan [9 ]
Im, Seock-Ah [10 ]
Saura, Cristina [11 ]
Biganzoli, Laura [12 ]
Sohn, Joohyuk [13 ]
Levy, Christelle [14 ]
Jacot, William [15 ]
Begbie, Natasha [16 ]
Ke, Jun [17 ]
Patel, Gargi Surendra [18 ]
Bardia, Aditya
机构
[1] Univ Milan, Milan, Italy
[2] IRCCS, European Inst Oncol, Milan, Italy
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[5] Natl Canc Ctr, Tokyo, Japan
[6] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil
[7] Baylor Univ, US Oncol Network, Texas Oncol, Med Ctr, Dallas, TX USA
[8] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium
[9] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[11] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[12] Santo Stefano Hosp, Azienda USL Toscana Ctr, Dept Oncol, Prato, Italy
[13] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[14] Ctr Francois Baclesse, Caen, France
[15] Univ Montpellier, Inst Canc Montpellier, Dept Med Oncol, Montpellier, France
[16] AstraZeneca, Clin Dev, Late Stage Dev, Oncol R&D, Cambridge, England
[17] AstraZeneca, Biometr Oncol, Late Stage Dev, Oncol R&D, Waltham, MA USA
[18] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
关键词
D O I
10.1200/JCO.2024.42.17_suppl.LBA1000
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
LBA1000
引用
收藏
页码:LBA1000 / LBA1000
页数:1
相关论文
empty
未找到相关数据